<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/54C9C520-1126-4FF5-841A-20624B5F7DF9"><gtr:id>54C9C520-1126-4FF5-841A-20624B5F7DF9</gtr:id><gtr:name>Physics Ipswich Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BD4E456F-AC31-4992-90AA-CACDC2DD4989"><gtr:id>BD4E456F-AC31-4992-90AA-CACDC2DD4989</gtr:id><gtr:name>Torbay Hospital</gtr:name><gtr:address><gtr:line1>Lawes Bridge</gtr:line1><gtr:postCode>TQ2 7AA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29"><gtr:id>7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29</gtr:id><gtr:name>Royal Preston Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54C9C520-1126-4FF5-841A-20624B5F7DF9"><gtr:id>54C9C520-1126-4FF5-841A-20624B5F7DF9</gtr:id><gtr:name>Physics Ipswich Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BD4E456F-AC31-4992-90AA-CACDC2DD4989"><gtr:id>BD4E456F-AC31-4992-90AA-CACDC2DD4989</gtr:id><gtr:name>Torbay Hospital</gtr:name><gtr:address><gtr:line1>Lawes Bridge</gtr:line1><gtr:postCode>TQ2 7AA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29"><gtr:id>7140F2B7-4F80-40FD-9EF7-C5B2B43D5C29</gtr:id><gtr:name>Royal Preston Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0275454D-4FEC-4FDE-8A13-6ED31A4D624A"><gtr:id>0275454D-4FEC-4FDE-8A13-6ED31A4D624A</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Evans</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_11001"><gtr:id>5DA3CB63-2251-4125-8461-DF8DDA0C6186</gtr:id><gtr:title>Evaluation of Image Guided Radiotherapy (IGRT) for more accurate Partial Breast Intensity-Modulated Radiotherapy: comparison with standard imaging technique</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_11001</gtr:grantReference><gtr:abstractText>Radiotherapy is an effective treatment which kills any remaining cancer cells left after surgery and improves the cure rate for women with early breast cancer. Studies have shown that a subgroup of mainly younger women have a higher than average risk of the cancer returning after treatment and have poorer chances of survival. Since most of these tumour recurrences occur close to the site of original cancer, we call this area the tumour bed, a boost dose of radiotherapy is given to this area for the higher risk group of women. Radiotherapy is normally given daily for 3 or more weeks and in order to ensure that the tumour bed is always in the area targeted by the radiotherapy machine, a safety margin is added around the known tumour bed position. This safety margin accounts for daily variations in patient and breast position, including breathing motion during treatment. Checks on treatment accuracy are currently limited to images of the lung and bones. Because we cannot see the tumour bed directly, the added safety margin means that we have to boost (give a high dose to) up to twice as much healthy breast tissue than we really need to. The UK IMPORT HIGH trial tests a more efficient and effective way of delivering a boost using advanced radiotherapy techniques. An important innovation is a national agreement with breast cancer surgeons to mark the walls of the surgical excision cavity with small titanium clips that can be imaged during radiotherapy. We can now directly image the tumour bed before each treatment (this is called image guided radiotherapy, or IGRT). Our pilot studies suggest that safety margins around the tumour bed can be greatly reduced, leading us to expect a lower rate of long-term complications (breast shrinkage, hardness, pain and rib fracture). The IMPORT HIGH trial offers a unique opportunity to compare standard imaging and IGRT within the same patient. The main outcome measure is accuracy of radiotherapy with IGRT compared with standard imaging. It will be possible to calculate the margin of healthy tissue that would need to have been added around the tumour bed if standard imaging had been used. The study team consists of oncology, physics, radiography, statistics and radiobiology specialists. The study will cost &amp;pound;312,082 for a full time researcher and a physicist for 2.5 years.</gtr:abstractText><gtr:technicalSummary>RESEARCH DESIGN: Multi-centre observational study embedded within a national phase III randomised controlled trial: IMPORT (Intensity Modulated Partial Organ Radiotherapy) HIGH. STUDY POPULATION: Patients receiving breast radiotherapy as part of IMPORT HIGH. Eligibility criteria for IMPORT HIGH includes any patient where a high dose boost to the tumour bed is deemed beneficial. PLANNED INTERVENTIONS: There will be no direct intervention in the patients? treatment. Experimental intervention is image guided radiotherapy (IGRT) and the control intervention is standard imaging. IMPORT HIGH patients receive IGRT as routine. OUTCOME MEASURES, ASSESSMENT AND TIMETABLE: Project duration is 30 months. The main project tasks are the evaluation of the outcome measures. Primary outcome measure: positional accuracy of IGRT versus standard imaging. This will be assessed using the mean absolute difference between the set-up errors measured using IGRT and standard imaging for all patients (months 1 -12). Secondary outcome measures: (1) Volume of normal tissue spared using IGRT compared to standard imaging: From the positional accuracy of IGRT versus standard imaging we can determine the required safety margins and tumour bed boost volume required for standard imaging. We will re-plan patients using this volume and determine the difference in the treated volume of tissue (volume that receives 95% of the prescribed dose to the tumour bed) for standard imaging and for IGRT (months 12 -24). (2) Differences in modelled risk of adverse effects, expressed in terms of normal tissue complication probability: Using existing trial data we will determine the relationship between volume of tissue treated and the risk of fibrosis. For each patient, the percentage reduction in rate of fibrosis achieved by the use of IGRT in preference to standard imaging will be estimated (months 21-27). (3) The time required to perform IGRT and standard imaging: This will be recorded during the study (months 1-12). STATISTICAL ANALYSIS: Each patient acts as their own control, paired analyses will be done comparing accuracy of the two techniques using either the t-test or the Wilcoxon rank-sum test. Distributions of random and systematic positional errors will be compared between centres using parametric or non-parametric analysis of variance (as appropriate). SAMPLE SIZE AND RECRUITMENT: Sample size calculation is based on the aim to compare techniques in terms of the measured overall set-up errors. We estimate the maximum sample size is 250 patients (see attached project protocol for details). We have arranged for an Independent Data Monitoring Committee to confidentially review the data after the first 100 patients, and give advice on the final sample size. IMPORT HIGH accural is predicted to have reached 400 patients by the end of the first year of the proposed study.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>313593</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>IMPORT IGRT</gtr:description><gtr:id>AAF957B2-B418-422C-8388-322EDD7400DD</gtr:id><gtr:impact>This has informed national IMPORT IGRT breast radiotherapy trial</gtr:impact><gtr:outcomeId>YZjsFaXU5Yc-1</gtr:outcomeId><gtr:partnerContribution>Access to patient related data and specialist expertisePatient data and expertisePatient data and expertisePatient data and expertisePatient data and expertise</gtr:partnerContribution><gtr:piContribution>This is the collaboration that makes this project work and made possible by the funding</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Preston Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IMPORT IGRT</gtr:description><gtr:id>615C6ED2-604E-48C1-9AD4-B45616DD242B</gtr:id><gtr:impact>This has informed national IMPORT IGRT breast radiotherapy trial</gtr:impact><gtr:outcomeId>YZjsFaXU5Yc-5</gtr:outcomeId><gtr:partnerContribution>Access to patient related data and specialist expertisePatient data and expertisePatient data and expertisePatient data and expertisePatient data and expertise</gtr:partnerContribution><gtr:piContribution>This is the collaboration that makes this project work and made possible by the funding</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Physics Ipswich Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IMPORT IGRT</gtr:description><gtr:id>C289A940-F628-400E-98F8-AE64C98B7579</gtr:id><gtr:impact>This has informed national IMPORT IGRT breast radiotherapy trial</gtr:impact><gtr:outcomeId>YZjsFaXU5Yc-3</gtr:outcomeId><gtr:partnerContribution>Access to patient related data and specialist expertisePatient data and expertisePatient data and expertisePatient data and expertisePatient data and expertise</gtr:partnerContribution><gtr:piContribution>This is the collaboration that makes this project work and made possible by the funding</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IMPORT IGRT</gtr:description><gtr:id>12F7C54A-22A4-4F22-92FC-D9A018A6A2BD</gtr:id><gtr:impact>This has informed national IMPORT IGRT breast radiotherapy trial</gtr:impact><gtr:outcomeId>YZjsFaXU5Yc-2</gtr:outcomeId><gtr:partnerContribution>Access to patient related data and specialist expertisePatient data and expertisePatient data and expertisePatient data and expertisePatient data and expertise</gtr:partnerContribution><gtr:piContribution>This is the collaboration that makes this project work and made possible by the funding</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Torbay Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IMPORT IGRT</gtr:description><gtr:id>F10861CC-FC1B-4645-A552-0F0AFE5BC550</gtr:id><gtr:impact>This has informed national IMPORT IGRT breast radiotherapy trial</gtr:impact><gtr:outcomeId>YZjsFaXU5Yc-4</gtr:outcomeId><gtr:partnerContribution>Access to patient related data and specialist expertisePatient data and expertisePatient data and expertisePatient data and expertisePatient data and expertise</gtr:partnerContribution><gtr:piContribution>This is the collaboration that makes this project work and made possible by the funding</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>08336F6D-B7E8-4155-8194-996C10976E46</gtr:id><gtr:title>Does breast composition influence late adverse effects in breast radiotherapy?</gtr:title><gtr:parentPublicationTitle>Breast (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e8b4766f6d4320f7393680c595fc7"><gtr:id>ab2e8b4766f6d4320f7393680c595fc7</gtr:id><gtr:otherNames>Juneja P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-9776</gtr:issn><gtr:outcomeId>56cb37eb842006.57388257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2938685E-CEBB-4EC1-BD80-7100F4099DD5</gtr:id><gtr:title>Classification of fibroglandular tissue distribution in the breast based on radiotherapy planning CT.</gtr:title><gtr:parentPublicationTitle>BMC medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e8b4766f6d4320f7393680c595fc7"><gtr:id>ab2e8b4766f6d4320f7393680c595fc7</gtr:id><gtr:otherNames>Juneja P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2342</gtr:issn><gtr:outcomeId>56cb37eb5a4bd2.21662094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACF273CF-6C12-483A-837B-C4F40F984700</gtr:id><gtr:title>Optimization and comparison of balloon-based partial breast brachytherapy using a single source, a standard plan line source, and both forward and inverse planned multilumen techniques.</gtr:title><gtr:parentPublicationTitle>Brachytherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/328217a3d44247c97e2fe089266c68fc"><gtr:id>328217a3d44247c97e2fe089266c68fc</gtr:id><gtr:otherNames>Eyre K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-4721</gtr:issn><gtr:outcomeId>pm_12581_21_22732322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2CF685E-5F5E-4742-9104-56341D98B9EB</gtr:id><gtr:title>Clinical implementation of kilovoltage cone beam CT for the verification of sequential and integrated photon boost treatments for breast cancer patients.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a8b74fa59af80f006a4b19e6f38720"><gtr:id>b6a8b74fa59af80f006a4b19e6f38720</gtr:id><gtr:otherNames>Donovan EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>pm_12581_21_22553296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89BA28D0-68E5-4EE1-876D-72B061070B8C</gtr:id><gtr:title>The effect of image guidance on dose distributions in breast boost radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6a8b74fa59af80f006a4b19e6f38720"><gtr:id>b6a8b74fa59af80f006a4b19e6f38720</gtr:id><gtr:otherNames>Donovan EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>545cd85d55e333.36690480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F77AD715-F437-4BEE-B61B-5C544D0034AC</gtr:id><gtr:title>How does imaging frequency and soft tissue motion affect the PTV margin size in partial breast and boost radiotherapy?</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0b3e447402b34af59db14b2f74462b9"><gtr:id>c0b3e447402b34af59db14b2f74462b9</gtr:id><gtr:otherNames>Harris EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_12581_21_22521748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16A3BC8B-6ABD-4C84-A62C-ABE6ACA30127</gtr:id><gtr:title>Tumour bed delineation for partial breast/breast boost radiotherapy: what is the optimal number of implanted markers?</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e266c458473c90a492c8e0a1964cc80"><gtr:id>6e266c458473c90a492c8e0a1964cc80</gtr:id><gtr:otherNames>Kirby AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>545cd8f4318797.45530459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F8DDD90-F9B0-4A29-B236-1968A826941C</gtr:id><gtr:title>A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0b3e447402b34af59db14b2f74462b9"><gtr:id>c0b3e447402b34af59db14b2f74462b9</gtr:id><gtr:otherNames>Harris EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>56cb37eb3068d6.73538253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2297FC8A-B952-4306-B317-BDCE3A084EA1</gtr:id><gtr:title>A multicentre observational study evaluating image-guided radiotherapy for more accurate partial-breast intensity-modulated radiotherapy: comparison with standard imaging technique</gtr:title><gtr:parentPublicationTitle>Efficacy and Mechanism Evaluation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b5de1d981332a350b2c81c56a19507c"><gtr:id>4b5de1d981332a350b2c81c56a19507c</gtr:id><gtr:otherNames>Harris E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56cb373c1370b7.89880452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>746B17B5-2C1B-476B-8303-96ABBC6CF95F</gtr:id><gtr:title>Investigation of the accuracy of breast tissue segmentation methods for the purpose of developing breast deformation models for use in adaptive radiotherapy</gtr:title><gtr:parentPublicationTitle>Journal of Physics: Conference Series</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e8b4766f6d4320f7393680c595fc7"><gtr:id>ab2e8b4766f6d4320f7393680c595fc7</gtr:id><gtr:otherNames>Juneja P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd85d7bd131.02985334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0ABE803-A234-42A1-A588-EA3122463F15</gtr:id><gtr:title>Association of breast tumour bed seroma with post-operative complications and late normal tissue toxicity: results from the Cambridge Breast IMRT trial.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a59e1f40bd4e6892376678e5aaea96"><gtr:id>c7a59e1f40bd4e6892376678e5aaea96</gtr:id><gtr:otherNames>Mukesh MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>pm_12581_21_22704052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5387859C-EBAA-4765-99B4-B5824C8A1BD0</gtr:id><gtr:title>Relationship between irradiated breast volume and late normal tissue complications: a systematic review.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/477f0e6a7504660e515d2fec30aa83bc"><gtr:id>477f0e6a7504660e515d2fec30aa83bc</gtr:id><gtr:otherNames>Mukesh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_12581_21_22682540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B400CFA8-C9ED-4869-8F34-6368BCB363B4</gtr:id><gtr:title>Adaptive breast radiation therapy using modeling of tissue mechanics: a breast tissue segmentation study.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e8b4766f6d4320f7393680c595fc7"><gtr:id>ab2e8b4766f6d4320f7393680c595fc7</gtr:id><gtr:otherNames>Juneja P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>545cd8f4599e06.31583230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C3E7DAC-6D79-453D-911B-E7B48B0B4616</gtr:id><gtr:title>The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e22b1d43bc12a5173d191f77a36766b"><gtr:id>5e22b1d43bc12a5173d191f77a36766b</gtr:id><gtr:otherNames>Bartlett FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>589a21b181f0f6.79719900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6B93C61-92E5-4762-A37C-E654D3BB5008</gtr:id><gtr:title>Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a59e1f40bd4e6892376678e5aaea96"><gtr:id>c7a59e1f40bd4e6892376678e5aaea96</gtr:id><gtr:otherNames>Mukesh MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>545cd8f40b9925.49288510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B803B9B-CE25-4312-BFD0-8744AD61E702</gtr:id><gtr:title>The validation index: a new metric for validation of segmentation algorithms using two or more expert outlines with application to radiotherapy planning.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e8b4766f6d4320f7393680c595fc7"><gtr:id>ab2e8b4766f6d4320f7393680c595fc7</gtr:id><gtr:otherNames>Juneja P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn><gtr:outcomeId>545cd85da00fe1.72498833</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_11001</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>